CanRIO Member Publications

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Posted February 23, 2021
Ann Rheum Dis 2020 Background: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given… Read More

Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology

Posted January 21, 2021

Cancer Immunol Immunother 2021
Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases… Read More

Adverse Events Associated with Immune Checkpoint Blockade

Posted January 18, 2021

N Engl J Med 2018
A case of PR3-ANCA GPA developing after checkpoint blockade is described. Read More

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

Posted September 3, 2020

Sci Rep 2020
The ‘real-world’ patient population of metastatic melanoma is not fully represented in clinical trials investigating checkpoint inhibitors. We described therapy discontinuation… Read More

Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort

Posted August 19, 2020

Autoimmun Rev 2020
Objective: Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related… Read More

Moving towards personalized treatments of immune-related adverse events

Posted August 17, 2020

Nat Rev Clin Oncol 2020
The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour… Read More

Immune Checkpoint Inhibitors in Cancer Immunotherapy

Posted June 15, 2020
CMAJ 2020 Immune checkpoint inhibitors (ICI’s) are increasingly used in cancer immunotherapy, and have shown unprecedented survival benefit in a number of malignancies with historically… Read More

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy

Posted June 11, 2020

N Engl J Med 2020
A case description of the successful use of tofacitinib in a patient with gastric cancer receiving pembrolizumab whose… Read More

Checking in with immune checkpoint inhibitors: Results of a needs assessment survey of Canadian rheumatologists

Posted July 12, 2019

J Cancer Sci Therap 2019
Objectives: Immune checkpoint inhibitors (ICI) are associated with immune-related adverse events (irAE), including autoimmune rheumatologic diseases. The Canadian Research… Read More

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

Posted July 10, 2019

J Rheum 2019
Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune system to fight cancer cells. Their use… Read More